All News

In part 2 of our interview, Lissette Logan, PharmD, and Danielle Weaver, PharmD, discuss the evolution of contraceptive services and how pharmacy is supporting rural communities and their patients.

In part 3 of our interview with Bill Wolfe, COO of WriteWise, he discusses the technology backing his team’s approach to forever changing how pharmacy benefits are distributed in the US.

Since 2016, the rate of gabapentin prescribing slowed but is still increasing, especially for women and older adults.

This marks the first and only IL-23 approval for these indications in pediatric populations.

Amid recent measles outbreaks in Texas and Ohio, researchers aim to understand MMR vaccine coverage following postelimination outbreaks throughout the country.

Based on a new report detailing the current trends in PBM types from the Big 3 to new grassroots organizations, Bill Wolfe, COO of WriteWise, discusses a shifting pharmacy benefits landscape.

Researchers address impacts of the Inflation Reduction Act on the access, cost, and coverage of glucagon-like peptide-1 medications for patients with diabetes.

In the final part of our interview with Mark Garofoli, PharmD, BCGP, CPE, CTTS, he discusses what the future will hold regarding clinical decision-making following the reported acetaminophen-autism link.

Pharmacists are on the front line for patients looking to self-manage their menstrual pain, making their role invaluable in women’s health.

Amid the prominent use of vaping in today’s society, researchers assess how it impacts pregnancy outcomes, including preterm birth, low birth weight, and small for gestational age.

The study results highlight the importance of pneumococcal vaccination for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease.

Investigators examine the effects of combination therapy with metformin combined with sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, or thiazolidinediones.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, also known as “the Pain Guy,” discusses his initial reactions upon learning about the Trump Administration linking acetaminophen use with autism.

Further, after the introduction of the pneumococcal conjugate vaccine 10, investigators note a decrease of infections caused by multidrug resistance infection.

In part 3 of our interview with Rae McMahan, she explores her role at Prescryptive Health and how she’s helping pharmacy stakeholders navigate complex GLP-1 prescription drug benefits.

The model is designed to increase access, utilization, and adherence to insulin by lowering its maximum price.

Along with the Senior Care Pharmacy Coalition, 3 additional long-term care advocacy groups have joined in on calls to pass the Preserving Patient Access to Long-Term Care Pharmacies Act.

As part of this announcement, the administration launches initiatives across the National Institutes of Health, the FDA, and the Center for Medicare & Medicaid Services.

Through her work as senior vice president of payor solutions at Prescryptive Health, Rae McMahan shares insights into how increased GLP-1 popularity and costs impact pharmacies.

As their scope of practice continues to expand, researchers issue a survey on how community pharmacists conduct point-of-care testing for acute upper respiratory tract infections.

The vote for state and local jurisdictions requiring a prescription for administration of COVID-19 vaccines failed after a tiebreaker vote from the committee chair.

Rae McMahan, senior vice president of payor solutions at Prescryptive Health, discusses GLP-1 access, advertising, and the challenges that often accompany this drug class.

The clinical impact of sodium-glucose cotransporter 2 inhibitors on adults with type 2 diabetes calls for further research on the risk factors of treatment failure and patients’ economic outcomes.

Bumetanide nasal spray is available in 0.5 mg, which is an alternative to traditional oral and intravenous formulations for outpatient therapies.

FDA approves ruxolitinib cream for children with atopic dermatitis, offering a new nonsteroidal treatment option for better symptom management.

This year’s event, from October 18-21, 2025, will take place in New Orleans, Louisiana, at the Ernest N. Morial Convention Center.

The recommendations are provided through the West Coast Health Alliance and pull from guidance from the American Academy of Pediatrics and other organizations.

Hyperkalemia, chronic kidney disease, and hypertension often don’t manifest until the diseases become chronically uncontrolled, according to Ralph J. Riello III, PharmD, BCPS.